- Home
- NUTX
NUTX
Nutex Health Inc.
as of 03-19-2026 3:31pm EST
Nutex Health Inc is a physician-led, healthcare services and operations company with various hospital facilities in the U.S. states (hospital division), and a primary care-centric, risk-bearing population health management division. The company has three segments: the hospital division, the PHM division, and the real estate division. The hospital division implements and operates health care models, including micro-hospitals, specialty hospitals and hospital outpatient departments (HOPDs). The population health management (PHM) division owns and operates provider networks such as independent physician associations (IPAs). The Real Estate Entities own the land and hospital buildings which are leased to its hospital entities. The majority of the revenue is derived from the Hospital division.
| Founded: | 2011 | Country: | United States |
| Employees: | 944 | City: | HOUSTON |
| Market Cap: | 655.4M | IPO Year: | 2009 |
| Target Price: | $252.50 | AVG Volume (30 days): | 163.2K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 10.48 | EPS Growth: | 7.93 |
| 52 Week Low/High: | $45.88 - $193.07 | Next Earning Date: | 03-05-2026 |
| Revenue: | $875,257,000 | Revenue Growth: | 82.36% |
| Revenue Growth (this year): | 8.28% | Revenue Growth (next year): | 1.96% |
| P/E Ratio: | 9.01 | Index: | N/A |
| Free Cash Flow: | 245.6M | FCF Growth: | +1057.31% |
AI-Powered NUTX Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Nutex Health Inc. (NUTX)
Director
Avg Cost/Share
$94.46
Shares
10
Total Value
$944.60
Owned After
32,137
SEC Form 4
Chief Legal Officer-Healthcare
Avg Cost/Share
$88.87
Shares
79
Total Value
$7,020.72
Owned After
2,758
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Spears Kelvin | NUTX | Director | Mar 17, 2026 | Buy | $94.46 | 10 | $944.60 | 32,137 | |
| Montgomery Pamela W. | NUTX | Chief Legal Officer-Healthcare | Mar 13, 2026 | Buy | $88.87 | 79 | $7,020.72 | 2,758 |
Earnings Transcripts
SEC 8-K filings with transcript text
2025 Q4 Q4 2025 Earnings
8-K BUY Mar 5, 2026 · 100% conf.
Q4 2025 Earnings
8-K BUYMar 5, 2026 · 100% conf.
1D
+19.60%
$125.99
Act: -13.80%
5D
+27.13%
$133.92
20D
+56.02%
$164.36
nutx-202603050001479681FALSE00014796812026-03-052026-03-05
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported) March 5, 2026
NUTEX HEALTH INC.
(Exact name of registrant as specified in its charter)
Delaware 001-41346 11-3363609
(State or Other Jurisdiction of Incorporation)(Commission File Number)(I.R.S. Employer Identification Number)
1776 Yorktown St, Suite 700, Houston, Texas 77056 (Address of principal executive offices) (zip code) (713) 660-0557 (Registrant’s telephone number, including area code) N/A (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) o Precommencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) o Precommencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbols(s)Name of each exchange on which registered Common Stock, $0.001 par valueNUTXThe NASDAQ Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company o If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Item 2.02. Results of Operations and Financial Condition On March 5, 2026, Nutex Health Inc. (the “Company”) announced its financial and operating results for the fourth quarter and year ending December 31, 2025. A copy of the Company’s press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
Item 9.01 Financial Statements and Exhibits (d)Exhibits
Exhibit No.Description of Exhibit 99.1Press Release dated March 5, 2026
104Cover Page Interactive Data File - the cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
THE INFORMATION CONTAINED IN ITEM 2.02 OF THIS CURRENT REPORT, INCLUDING EXHIBIT 99.1 ATTACHED HERETO, SHALL NOT BE DEEMED “FILED” FOR THE PURPOSES OF SECTION 18 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, NOR SHALL IT BE DEEMED INCORPORATED BY REFERENCE INTO ANY REGISTRATION STATEMENT OR OTHER FILING PURSUANT TO THE SECURITIES ACT OF 1933, AS AMENDED, EXCEPT AS OTHERWISE EXPRESSLY STATED IN SUCH FILING
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Date: March 5, 2026
Nutex Health Inc.
By: /s/ Jon C. Bates
Jon C. Bates Chief Financial Officer
2025 Q3 Q3 2025 Earnings
8-K BUY Nov 19, 2025 · 100% conf.
Q3 2025 Earnings
8-K BUYNov 19, 2025 · 100% conf.
1D
+21.35%
$136.14
Act: +26.87%
5D
+33.91%
$150.24
Act: +0.54%
20D
+55.24%
$174.17
Act: +48.71%
nutx-202511190001479681FALSE00014796812025-11-182025-11-18
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported) November 19, 2025
NUTEX HEALTH INC.
(Exact name of registrant as specified in its charter)
Delaware001-4134611-3363609 (State or Other Jurisdiction of Incorporation)(Commission File Number)(I.R.S. Employer Identification Number)
6030 S. Rice Ave, Suite C, Houston, Texas 77081 (Address of principal executive offices) (zip code) (713) 660-0557 (Registrant’s telephone number, including area code) N/A (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) o Precommencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) o Precommencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbols(s)Name of each exchange on which registered Common Stock, $0.001 par valueNUTXNASDAQ Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company o If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Item 2.02. Results of Operations and Financial Condition On November 19, 2025, Nutex Health Inc. (the “Company”) announced its financial and operating results for the third quarter ending September 30, 2025. A copy of the Company’s press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
Item 9.01 Financial Statements and Exhibits (d)Exhibits
Exhibit No.Description of Exhibit 99.1Press Release dated November 19, 2025
104Cover Page Interactive Data File - the cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
THE INFORMATION CONTAINED IN ITEM 2.02 OF THIS CURRENT REPORT, INCLUDING EXHIBIT 99.1 ATTACHED HERETO, SHALL NOT BE DEEMED “FILED” FOR THE PURPOSES OF SECTION 18 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, NOR SHALL IT BE DEEMED INCORPORATED BY REFERENCE INTO ANY REGISTRATION STATEMENT OR OTHER FILING PURSUANT TO THE SECURITIES ACT OF 1933, AS AMENDED, EXCEPT AS OTHERWISE EXPRESSLY STATED IN SUCH FILING
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Date: November 19, 2025
Nutex Health Inc.
By: /s/ Jon C. Bates
Jon C. Bates Chief Financial Officer
2025 Q3 Q3 2025 Earnings
8-K BUY Nov 18, 2025 · 100% conf.
Q3 2025 Earnings
8-K BUYNov 18, 2025 · 100% conf.
1D
+21.35%
$136.14
Act: +26.87%
5D
+33.91%
$150.24
Act: +0.54%
20D
+55.24%
$174.17
Act: +48.71%
nutx-202511180001479681FALSE00014796812025-11-182025-11-18
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported) November 18, 2025
NUTEX HEALTH INC.
(Exact name of registrant as specified in its charter)
Delaware001-4134611-3363609 (State or Other Jurisdiction of Incorporation)(Commission File Number)(I.R.S. Employer Identification Number)
6030 S. Rice Ave, Suite C, Houston, Texas 77081 (Address of principal executive offices) (zip code) (713) 660-0557 (Registrant’s telephone number, including area code) N/A (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) o Precommencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) o Precommencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbols(s)Name of each exchange on which registered Common Stock, $0.001 par valueNUTXNASDAQ Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company o If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Item 2.02. Results of Operations and Financial Condition On November 18, 2025, Nutex Health Inc. (the “Company”) announced its financial and operating results for the second quarter ending June 30, 2025. A copy of the Company’s press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
Item 9.01 Financial Statements and Exhibits (d)Exhibits
Exhibit No.Description of Exhibit 99.1Press Release dated November 14, 2025
104Cover Page Interactive Data File - the cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
THE INFORMATION CONTAINED IN ITEM 2.02 OF THIS CURRENT REPORT, INCLUDING EXHIBIT 99.1 ATTACHED HERETO, SHALL NOT BE DEEMED “FILED” FOR THE PURPOSES OF SECTION 18 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, NOR SHALL IT BE DEEMED INCORPORATED BY REFERENCE INTO ANY REGISTRATION STATEMENT OR OTHER FILING PURSUANT TO THE SECURITIES ACT OF 1933, AS AMENDED, EXCEPT AS OTHERWISE EXPRESSLY STATED IN SUCH FILING
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Date: November 18, 2025
Nutex Health Inc.
By: /s/ Jon C. Bates
Jon C. Bates Chief Financial Officer
Compare NUTX vs Leading Stocks
See how NUTX stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "NUTX Nutex Health Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.